The Library
Comparison of health technology assessment for new medicines in France and England : an example based on ixazomib for patients with relapsed or refractory multiple myeloma
Tools
Tools
Tools
Armoiry, Xavier, Spath, Hans-Martin, Clarke, Aileen, Connock, Martin, Sutcliffe, Paul and Dussart, Claude (2019) Comparison of health technology assessment for new medicines in France and England : an example based on ixazomib for patients with relapsed or refractory multiple myeloma. Journal of Market Access & Health Policy, 7 (1). 1648971. doi:10.1080/20016689.2019.1648971 ISSN 2001-6689.
|
PDF
WRAP-Comparison-health-technology-medicines-France-England-Clarke-2019.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons: Attribution-Noncommercial 4.0. Download (915Kb) | Preview |
Official URL: https://doi.org/10.1080/20016689.2019.1648971
Abstract
Introduction: The appraisal of medicines is often a complex and iterative process. We compared the health technology assessment (HTA) process in England and France taking as a case study the example of ixazomib for multiple myeloma.
Methods: We undertook an analysis of eight relevant published documents identifed from the websites of the French and English HTA bodies (HAS and NICE, respectively). We analyse patients’ availability of ixazomib resulting in the different stages of the appraisal process.
Results: We identified differences in the assessment, one of these being the use of an appraisal scope in England allowing the differentiation of populations and comparators according to previously approved treatments. Ixazomib became available earlier in France as part of an early access programme, but the availability was soon discontinued for newly eligible patients following an HAS determination that Ixazomib yielded no additional benefit. This opinion resulted in long pricing discussions. In England, despite the absence of an early access programme and following a process that included cost-effectiveness evaluation combined with pricing discussions, the medicine was fairly rapidly recommended for use.
Conclusions: Differences in the HTA process may result in appreciable differences in time from marketing authorisation to health service adoption of newly licensed drugs
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine |
||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
| SWORD Depositor: | Library Publications Router | ||||||
| Library of Congress Subject Headings (LCSH): | Medical technology -- Evaluation -- England, Medical technology -- Evaluation -- France, Multiple myeloma , Multiple myeloma -- Treatment | ||||||
| Journal or Publication Title: | Journal of Market Access & Health Policy | ||||||
| Publisher: | Informa UK Limited | ||||||
| ISSN: | 2001-6689 | ||||||
| Official Date: | 30 July 2019 | ||||||
| Dates: |
|
||||||
| Volume: | 7 | ||||||
| Number: | 1 | ||||||
| Article Number: | 1648971 | ||||||
| DOI: | 10.1080/20016689.2019.1648971 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Reuse Statement (publisher, data, author rights): | ** Article version: VoR ** From Crossref via Jisc Publications Router ** History: epub 30-07-2019. ** Licence for VoR version of this article starting on 01-01-2019: http://creativecommons.org/licenses/by-nc/4.0/ | ||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||
| Date of first compliant deposit: | 12 August 2019 | ||||||
| Date of first compliant Open Access: | 12 August 2019 | ||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
